TY  - GEN
AU  - Dang,Chau
AU  - Iyengar,Neil
AU  - Datko,Farrah
AU  - D'Andrea,Gabriella
AU  - Theodoulou,Maria
AU  - Dickler,Maura
AU  - Goldfarb,Shari
AU  - Lake,Diana
AU  - Fasano,Julie
AU  - Fornier,Monica
AU  - Gilewski,Theresa
AU  - Modi,Shanu
AU  - Gajria,Devika
AU  - Moynahan,Mary Ellen
AU  - Hamilton,Nicola
AU  - Patil,Sujata
AU  - Jochelson,Maxine
AU  - Norton,Larry
AU  - Baselga,Jose
AU  - Hudis,Clifford
TI  - Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
SN  - 1527-7755
PY  - 2015///0420
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - analysis
KW  - Breast Neoplasms
KW  - chemistry
KW  - Disease-Free Survival
KW  - Drug Administration Schedule
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunohistochemistry
KW  - In Situ Hybridization, Fluorescence
KW  - Infusions, Intravenous
KW  - Kaplan-Meier Estimate
KW  - Middle Aged
KW  - Paclitaxel
KW  - Receptor, ErbB-2
KW  - Trastuzumab
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2014.57.1745
ER  -